DelveInsight's  Diffuse Large B-cell Lymphoma - Epidemiology Forecast 2032 report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology of  Diffuse Large B-cell Lymphoma in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

 Diffuse Large B-cell Lymphoma Epidemiology Forecast |  Diffuse Large B-cell Lymphoma Prevalent population

DelveInsight's &lsquo;Diffuse Large B-cell Lymphoma - Epidemiology Forecast&ndash;2032&rsquo; report delivers an in-depth understanding of the disease, historical and forecasted epidemiology in the United States, EU4 (Germany, Spain, Italy, and France), the United Kingdom, and Japan.
<h2>Geography Covered</h2>
<ul>
<li>The United States</li>
<li>EU4 (Germany, France, Italy, and Spain), and the United Kingdom</li>
<li>Japan</li>
</ul>
Study Period: 2019-2032
<h2>Diffuse Large B-cell Lymphoma Disease Understanding</h2>
Diffuse Large B-cell Lymphoma Overview
Diffuse Large B-cell Lymphoma (DLBCL)&nbsp; is an aggressive (fast-growing) and the most common type of non-Hodgkin&rsquo;s lymphoma that can arise in lymph nodes or outside of the lymphatic system (such as in the gastrointestinal tract, testes, thyroid, skin, breast, bone, or brain). Often, the first sign of DLBCL includes painless, rapid swelling in the neck, underarms, or groin that is caused by enlarged lymph nodes. For some patients, the swelling may be painful. Other symptoms may include night sweats, fever, and unexplained weight loss. Patients may notice fatigue, loss of appetite, shortness of breath, or pain. Generally, it has been observed that DLBCL affects patients of all age groups with a wide range of presentations concerning localization, morphology, and molecular mechanisms.
&nbsp;
There are several subtypes of DLBCL. Classification of the DLBCL subtype requires examination of cell morphology (shape, structure, and form) as well as specialized tests including immunohistochemistry, flow cytometer, fluorescence in situ hybridization (FISH) and molecular testing.
&nbsp;
WHO/REAL classification
1. DLBCL, not otherwise specified (NOS):
<ul>
<li>T-cell/histiocyte rich large B-cell lymphoma</li>
<li>Primary DLBCL of the central nervous system (CNS)</li>
<li>Primary cutaneous DLBCL, leg type</li>
<li>Epstein-Barr virus (EBV)-positive DLBCL of the elderly</li>
<li>Germinal center B-cell (GCB)-DLBCL</li>
<li>Activated B-cell (ABC)-DLBCL</li>
</ul>
&nbsp;
2. DLBCL associated with chronic inflammation:
<ul>
<li>Primary mediastinal lymphoma</li>
<li>Intravascular large B-cell lymphoma</li>
<li>Anaplastic lymphoma kinase (ALK)-positive large B-cell lymphoma</li>
</ul>
<h2>Diffuse Large B-cell Lymphoma Epidemiology</h2>
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by total incident population of DLBCL, gender-specific population of DLBCL, age-specific population of DLBCL, type-specific population of DLBCL, and stage-specific population of DLBCL in the 7MM market covering the United States, EU4 countries (Germany, France, Italy, and Spain, the United Kingdom, and Japan from 2019 to 2032.
&nbsp;
Key Findings
This section provides glimpse of the DLBCL epidemiology in the 7MM
<h2>Diffuse Large B-cell Lymphoma Epidemiology</h2>
The epidemiology segment also provides the DLBCL epidemiology data and findings across the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
<ul>
<li>The total incident population of DLBCL in the 7MM comprised of 73,598 cases in 2021 and are projected to increase during the forecast period.</li>
<li>The total incident population of DLBCL in the United States is 29,958 in 2021.&nbsp;</li>
<li>The United States contributed to the largest incident population of DLBCL, accounting for ~ 41% of the 7MM in 2021.</li>
<li>Among EU4 countries, Germany accounted for the highest number of DLBCL cases, whereas Spain accounted for the lowest cases in 2021.</li>
<li>In Japan, the total incident population of DLBCL was 11,409 in 2021 and is anticipated to rise during the forecast period.</li>
<li>Among the total 26,064 cases of DLBCL, NOS type in 2021 in the US, GCB subtype accounts for 11,983 cases while ABC subtype accounts for 17,975 cases.</li>
<li>In 2021, males and females accounted for 16,777 and 13,182 cases respectively in the United States.</li>
<li>In 2021, the total cases of DLBCL in Stage I, Stage II, Stage III, and Stage IV were identified to be 7,190, 5,992, 5,093, and 11,684</li>
</ul>
<h2>Scope of the Report</h2>
<ul>
<li>The report covers the descriptive overview of DLBCL, explaining its causes, signs and symptoms, pathogenesis and diagnosis.</li>
<li>Comprehensive insight has been provided into the DLBCL epidemiology and treatment.</li>
<li>The report provides insight about the historical and forecasted patient pool of DLBCL in seven major markets covering the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.</li>
<li>The report helps to recognize the growth opportunities in the 7MM with respect to the patient population.</li>
<li>A detailed review of DLBCL epidemiology forecast is included in the report, covering the 7MM drug outreach.</li>
<li>The report provides an edge while developing business strategies, by understanding epidemiological trends.</li>
</ul>
<h2>Report Highlights</h2>
<ul>
<li>In the coming years, DLBCL market is anticipated to change in the coming years owing to the improvement in the diagnosis methodologies, raising awareness of the disease, increase in incidence population.</li>
<li>As per DelveInsight&rsquo;s analysis the major types of DLBCL include diffuse large B-cell lymphoma, NOS, germinal center B-cell-like or GCB subtype, non-GCB types, usually activated B-cell-like (ABC subtype), and others.</li>
<li>The report also encompasses other major segments, i.e., total incident population of DLBCL, gender-specific population of DLBCL, age-specific population of DLBCL, type-specific population of DLBCL, and stage-specific population of DLBCL.</li>
</ul>
<h2>DLBCL Report Insights</h2>
<ul>
<li>Patient Population</li>
<li>Eleven Years Forecast</li>
<li>7MM Coverage</li>
<li>DLBCL Epidemiology Segmentation</li>
</ul>
<h2>Key Questions</h2>
<ul>
<li>What is the disease risk, burden and unmet needs of DLBCL?</li>
<li>What is the historical DLBCL patient pool in the United States, EU4 (Germany, France, Italy, and Spain), the UK, and Japan?</li>
<li>What would be the forecasted patient pool of DLBCL at the 7MM level?</li>
<li>What will be the growth opportunities across the 7MM with respect to the patient population pertaining to DLBCL?</li>
<li>Out of the above-mentioned countries, which country would have the highest incident population of DLBCL during the study period (2019&ndash;2032)?</li>
<li>At what CAGR the population is expected to grow across the 7MM during the study period (2019&ndash;2032)?</li>
</ul>
<h2>Reasons to buy</h2>
<ul>
<li>The report will help in developing business strategies by understanding trends shaping and driving the DLBCL.</li>
<li>To understand the future market competition in the DLBCL market and Insightful review of the unmet needs.</li>
<li>Quantify patient populations in the global DLBCL market to improve product design, pricing, and launch plans.</li>
<li>Organize sales and marketing efforts by identifying the best opportunities for DLBCL in the US, EU4 (Germany, Spain, Italy, and France), the United Kingdom, and Japan.</li>
<li>The DLBCL epidemiology model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources.</li>
</ul>

1. Key Insights
2. Report Introduction
3. Executive Summary
4. Epidemiology Forecast Methodology
5. DLBCL Overview at a Glance in the 7MM
5.1. Patient Share (%) of DLBCL in 2019
5.2. Patient Share (%) of DLBCL in 2032
6. Disease Background and Overview
6.1. Introduction
6.2. Understanding Lymphoma
6.2.1. Types of Lymphoma
6.2.2. Types of Non-Hodgkin&rsquo;s Lymphomas (NHL)
6.3. Signs and symptoms of DLBCL
6.4. Pathophysiology
6.4.1. Molecular Events Involved in DLBCL Pathogenesis
6.4.2. Main oncogenes involved in the pathogenesis of DLBCL
6.4.3. Main tumor suppressor genes related to the pathogenesis and prognosis of DLBCL
6.4.4. Main transcription factors in the pathogenesis and prognosis of DLBCL
6.5. Classification of DLBCL
6.5.1. Based on Morphology
6.5.2. Based on molecular classification
6.5.3. Rare variants
6.5.4. Other DLBCLs
6.6. WHO classification of DLBCL
6.6.1. 2008 WHO classification
6.6.2. WHO classification of mature large B-cell lymphoid neoplasms
6.6.3. 2016 update of WHO classification of DLBCL: subtypes and related entities
6.7. DLBCL Diagnosis and staging
6.8. Staging
6.8.1. Ann Arbor staging
6.8.2. Cotswolds modification of Ann Arbor staging system
6.8.3. Lugano Modification of Ann Harbor
6.8.4. The International Prognostic Index staging system
6.9. Diagnostic guidelines
6.9.1. Spanish Lymphoma Group (GELTAMO) guidelines for the diagnosis, staging, of DLBCL
6.10. ESMO Clinical Practice Guidelines for diagnosis
6.10.1. Recommended diagnosis strategies in diffuse large B-cell lymphoma
6.11. DLBCL Biomarkers
6.11.1. Clinical prognostic markers in DLBCL
6.11.2. Molecular prognostic markers
7. Epidemiology and Patient Population of 7MM
7.1. Key Findings
7.1.1. Assumption and rationale
7.1.2. Total Incident cases of DLBCL in the 7MM
7.2. The United States
7.2.1. Total Incident cases of DLBCL in the US
7.2.2. Gender-specific cases of DLBCL in the US
7.2.3. Age-specific cases of DLBCL in the US
7.2.4. Type-specific Cases of DLBCL in the US
7.2.5. Stage-specific Incident Cases of DLBCL in the US
7.3. EU4 and the UK
7.3.1. Total Incident cases of DLBCL in EU4 and the UK
7.3.2. Gender-specific cases of DLBCL in EU4 and the UK
7.3.3. Age-specific cases of DLBCL in EU4 and the UK
7.3.4. Type-specific Cases of DLBCL in EU4 and the UK
7.3.5. Stage-specific incident cases of DLBCL in EU4 and the UK
7.4. Japan
7.4.1. Total Incident cases of DLBCL in Japan
7.4.2. Gender-specific cases of DLBCL in Japan
7.4.3. Age-specific cases of DLBCL in Japan
7.4.4. Type-specific Cases of DLBCL in Japan
7.4.5. Stage-specific Incident Cases of DLBCL in Japan
8. Appendix
8.1. Bibliography
8.2. Report Methodology
9. DelveInsight Capabilities
10. Disclaimer
11. About DelveInsight

DelveInsight's "Diffuse Large B-cell Lymphoma - Epidemiology Forecast to 2032" report delivers an in-depth understanding of the disease, historical and forecasted Diffuse Large B-cell Lymphoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Diffuse Large B-cell Lymphoma - Epidemiology Forecast - 2032

DelveInsight's  Diffuse Large B-cell Lymphoma - Epidemiology Forecast 2032 report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology..